MacKay Shields »

Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by MacKay Shields

Quarter-by-quarter ownership of Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by MacKay Shields from 13F filings

Historical chart of MacKay Shields investment in Alnylam Pharmaceuticals Inc Note 1.000 9/1

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals Inc Note 1.000 9/1 held by MacKay Shields consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals Inc Note 1.000 9/1 by MacKay Shields

Quarter filed Position value Share count Share price at filing
2024-03-31 $11M 12M 0.94
2023-12-31 $12M 12M 0.99
2023-09-30 $22M 23M 0.93

More positions owned by MacKay Shields

Gulfport Energy Corp Common Shares (GPOR)
Nice Note 9/1 (Principal)
Pioneer Nat Res Note 0.250% 5/1 (Principal)
Nrg Energy DBCV 2.750% 6/0 (Principal)
Microchip Technology Note 0.125%11/1 (Principal)
Biomarin Pharmaceutical Note 1.250% 5/1 (Principal)
Palo Alto Networks Note 0.375% 6/0 (Principal)
Ford Mtr Co Del Note 3/1 (Principal)
Exact Sciences Corp Note 0.375% 3/0 (Principal)
Southwest Airls Note 1.250% 5/0 (Principal)
Lantheus Hldgs Note 2.625%12/1 (Principal)
Vail Resorts Note 1/0 (Principal)
Integer Hldgs Corp Note 2.125% 2/1 (Principal)
Patrick Inds Note 1.750%12/0 (Principal)
Lumentum Hldgs Note 0.500%12/1 (Principal)

View all positions for MacKay Shields

Top funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1

Ubs Global Asset Management Americas
Readystate Asset Management
Steelhead Partners
Calamos Advisors
Aequim Alternative Investments
Davidson Kempner Capital Management
Wolverine Asset Management
Lazard Asset Management
Zazove Associates
Shenkman Capital Management
CNH Partners
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Capstone Investment Advisors
Citadel Advisors
MacKay Shields

View all funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1